1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Glioma in 14 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 7.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "The effect of staurosporine, a potent protein kinase C (PKC) inhibitor, on the sensitivity to radiation has been investigated in C6 glioma cells." | 7.68 | Sensitization of C6 glioma cells to radiation by staurosporine, a potent protein kinase C inhibitor. ( Nozawa, Y; Sakai, N; Yamada, H; Zhang, W, 1993) |
| " Imipramine increased the maximum response to 5-HT without altering the EC50 of the dose-response curve." | 5.30 | Chronic imipramine administration amplifies the serotonin2A receptor-induced intracellular Ca2+ mobilization in C6 glioma cells through a calmodulin-dependent pathway. ( Kamei, K; Muneoka, K; Muraoka, S; Takigawa, M, 1998) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 3.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "To investigate the possible mechanisms involved in forskolin-induced c-jun mRNA decrease in rat C6 glioma cells, we examined effects of a PKA inhibitor (H-89), a L-type Ca2+ channel blocker (nimodipine), a calmodulin activation inhibitor (calmidazolium chloride) and a Ca2+/calmodulin-dependent protein kinase II inhibitor (KN-62) on forskolin-induced c-jun mRNA down-regulation." | 3.70 | Activation of adenylate cyclase results in down-regulation of c-jun mRNA expression in rat C6 glioma cells. ( Choi, MR; Huh, SO; Kim, YH; Lee, JK; Song, DK; Suh, HW, 1999) |
| "The effect of staurosporine, a potent protein kinase C (PKC) inhibitor, on the sensitivity to radiation has been investigated in C6 glioma cells." | 3.68 | Sensitization of C6 glioma cells to radiation by staurosporine, a potent protein kinase C inhibitor. ( Nozawa, Y; Sakai, N; Yamada, H; Zhang, W, 1993) |
| "Malignant gliomas are characterized by high invasive potential and strong angiogenic ability." | 1.37 | HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. ( Nakabayashi, H; Shimizu, K, 2011) |
| " Imipramine increased the maximum response to 5-HT without altering the EC50 of the dose-response curve." | 1.30 | Chronic imipramine administration amplifies the serotonin2A receptor-induced intracellular Ca2+ mobilization in C6 glioma cells through a calmodulin-dependent pathway. ( Kamei, K; Muneoka, K; Muraoka, S; Takigawa, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Liu, X | 1 |
| Zhou, W | 1 |
| Yang, M | 1 |
| Ding, Y | 1 |
| Wang, Q | 1 |
| Hu, R | 1 |
| Nakabayashi, H | 1 |
| Shimizu, K | 1 |
| Kugaya, A | 2 |
| Kagaya, A | 2 |
| Uchitomi, Y | 2 |
| Motohashi, N | 1 |
| Yamawaki, S | 2 |
| Bouillon, M | 1 |
| Audette, M | 1 |
| Fukushima, D | 1 |
| Konishi, M | 1 |
| Maruyama, K | 1 |
| Miyamoto, T | 1 |
| Ishiura, S | 1 |
| Suzuki, K | 1 |
| Zhang, W | 1 |
| Yamada, H | 1 |
| Sakai, N | 1 |
| Nozawa, Y | 1 |
| Zensho, H | 1 |
| Oyamada, T | 1 |
| Tawara, Y | 1 |
| Inagaki, M | 1 |
| Muraoka, S | 1 |
| Kamei, K | 1 |
| Muneoka, K | 1 |
| Takigawa, M | 1 |
| Lee, JK | 1 |
| Choi, MR | 1 |
| Song, DK | 1 |
| Huh, SO | 1 |
| Kim, YH | 1 |
| Suh, HW | 1 |
| Perlman, JH | 1 |
| Gershengorn, MC | 1 |
| Masson, M | 1 |
| Albouz, S | 1 |
| Boutry, JM | 1 |
| Spezzatti, B | 1 |
| Castagna, M | 1 |
| Baumann, N | 1 |
| Shirazi, Y | 1 |
| McMorris, FA | 1 |
| Shin, ML | 1 |
| Press, RD | 1 |
| Misra, A | 1 |
| Gillaspy, G | 1 |
| Samols, D | 1 |
| Goldthwait, DA | 1 |
| Liscovitch, M | 1 |
| Slack, B | 1 |
| Blusztajn, JK | 1 |
| Wurtman, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Glioma
| Article | Year |
|---|---|
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Blotting, Western; Brain Neopl | 2011 |
Inhibition of serotonin-induced Ca2+ mobilization by interleukin-1 beta in rat C6BU-1 glioma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Calcium; Cell Division; Enz | 1995 |
Transduction of retinoic acid and gamma-interferon signal for intercellular adhesion molecule-1 expression on human tumor cell lines: evidence for the late-acting involvement of protein kinase C inactivation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Cell Adhesion Molecules; Enzyme Activation | 1993 |
Activation of the secretory pathway leads to a decrease in the intracellular amyloidogenic fragments generated from the amyloid protein precursor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Amyloid beta-Protein Precursor; Animals; C | 1993 |
Sensitization of C6 glioma cells to radiation by staurosporine, a potent protein kinase C inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Animals; Dose-Response Relationship, Radia | 1993 |
Modulation of endothelin-induced intracellular Ca2+ mobilization by interleukin-1 beta and lipopolysaccharide in C6 rat glioma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Endothelin-1; Enzyme Inhibitors; Ge | 1997 |
Chronic imipramine administration amplifies the serotonin2A receptor-induced intracellular Ca2+ mobilization in C6 glioma cells through a calmodulin-dependent pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antidepressive Agents, Tricyclic; Antipsycho | 1998 |
Activation of adenylate cyclase results in down-regulation of c-jun mRNA expression in rat C6 glioma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenylyl Cyclases; Animals; Calcium Channel Blockers; | 1999 |
Thyrotropin-releasing hormone stimulation of phosphoinositide hydrolysis desensitizes. Evidence against mediation by protein kinase C or calcium.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Cells, Cultured; Chlorides; Dose-Re | 1991 |
Calmodulin antagonist W-7 inhibits lysosomal sphingomyelinase activity in C6 glioma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calmodulin; Desipramine; Glioma; Isoquinolines; Lysos | 1989 |
Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte x C6 glioma cell hybrids.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetophenones; Animals; Arachidonic Acid; Arachidonic | 1989 |
Control of the expression of c-sis mRNA in human glioblastoma cells by phorbol ester and transforming growth factor beta 1.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Enzyme Activation; Gene Expression Regulation; Glioma | 1989 |
Differential regulation of phosphatidylcholine biosynthesis by 12-O-tetradecanoylphorbol-13-acetate and diacylglycerol in NG108-15 neuroblastoma x glioma hybrid cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Choline; Chromatography, High Pressure Liqui | 1987 |